1. Home
  2. MGNX vs QMCO Comparison

MGNX vs QMCO Comparison

Compare MGNX & QMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGNX
  • QMCO
  • Stock Information
  • Founded
  • MGNX 2000
  • QMCO 1980
  • Country
  • MGNX United States
  • QMCO United States
  • Employees
  • MGNX N/A
  • QMCO N/A
  • Industry
  • MGNX Biotechnology: Pharmaceutical Preparations
  • QMCO Electronic Components
  • Sector
  • MGNX Health Care
  • QMCO Technology
  • Exchange
  • MGNX Nasdaq
  • QMCO Nasdaq
  • Market Cap
  • MGNX 99.7M
  • QMCO 98.8M
  • IPO Year
  • MGNX 2013
  • QMCO N/A
  • Fundamental
  • Price
  • MGNX $1.82
  • QMCO $12.96
  • Analyst Decision
  • MGNX Hold
  • QMCO Hold
  • Analyst Count
  • MGNX 6
  • QMCO 2
  • Target Price
  • MGNX $3.20
  • QMCO $19.00
  • AVG Volume (30 Days)
  • MGNX 630.9K
  • QMCO 3.9M
  • Earning Date
  • MGNX 11-04-2025
  • QMCO 11-12-2025
  • Dividend Yield
  • MGNX N/A
  • QMCO N/A
  • EPS Growth
  • MGNX N/A
  • QMCO N/A
  • EPS
  • MGNX N/A
  • QMCO N/A
  • Revenue
  • MGNX $165,495,000.00
  • QMCO $266,079,000.00
  • Revenue This Year
  • MGNX N/A
  • QMCO N/A
  • Revenue Next Year
  • MGNX N/A
  • QMCO $7.66
  • P/E Ratio
  • MGNX N/A
  • QMCO N/A
  • Revenue Growth
  • MGNX 303.47
  • QMCO N/A
  • 52 Week Low
  • MGNX $0.99
  • QMCO $2.88
  • 52 Week High
  • MGNX $5.10
  • QMCO $90.64
  • Technical
  • Relative Strength Index (RSI)
  • MGNX 51.87
  • QMCO 71.78
  • Support Level
  • MGNX $1.69
  • QMCO $10.94
  • Resistance Level
  • MGNX $1.83
  • QMCO $15.33
  • Average True Range (ATR)
  • MGNX 0.10
  • QMCO 1.21
  • MACD
  • MGNX 0.00
  • QMCO 0.49
  • Stochastic Oscillator
  • MGNX 56.00
  • QMCO 72.99

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

About QMCO Quantum Corporation

Quantum Corp is a United States-based company that delivers end-to-end data management solutions designed for unstructured data in the era of artificial intelligence (AI). It provides one of the comprehensive and cost-efficient solutions for the entire data lifecycle. The group provides solutions for video, images, audio, and other large files because this unstructured data represents. Its portfolio of products includes primary storage software and systems, secondary storage software and systems, as well as devices and media. The group operates in three geographic regions: Americas, Europe, the Middle East, and Africa (EMEA), and Asia Pacific (APAC).

Share on Social Networks: